MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MediciNova, Inc.NASDAQ: MNOV
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $4.26K fell 17.7% year over year, behind the -8.2% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +4.3% a year.
Context
- Depreciation & amortization amounted to 4.9% of revenue in FY2025.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -17.7% toward the trailing-twelve-month pace of -8.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 20.1K USD
- Year-over-year change
- -4.6%
- 4-year CAGR
- -6.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.1K | -4.6% |
| FY2024 | 2024-12-31 | 21.08K | +3.9% |
| FY2023 | 2023-12-31 | 20.3K | +14.6% |
| FY2022 | 2022-12-31 | 17.71K | -32.3% |
| FY2021 | 2021-12-31 | 26.15K | — |
Depreciation & Amortization vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 depreciation & amortization of $19.18K is the 10th largest of the 11 companies compared; the peer median is $1.39M.
- Its year-over-year change of -8.2% is the 4th highest of 10, against a peer median of -13.3%.
- Depreciation & amortization amounts to 3.2% of revenue for MNOV, versus a peer median of 19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.74M | -13.3% | +13.9% | 3.0% | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.46M | -18.2% | +56.9% | 127.4% |
| LTM Mar 2026 | $5.17M | +4.4% | -20.7% | 7.8% | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M | -10.2% | -13.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.21M | +8.3% | +36.2% | — |
| LTM Mar 2026 | $960K | -46.5% | +26.8% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $131K | -84.0% | -41.1% | — | |
| LTM Mar 2026 | $19.18K | -8.2% | +4.3% | 3.2% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding MNOV) | $1.39M | -13.3% | +13.9% | 19.7% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K |
| Change in Working Capital | (1.21M) | 334.1K | 111.99K | (979.56K) | 1.17M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.03M) | 329.01K | 19.24K | (312.35K) | 459.87K |
| Other Working Capital | (181.42K) | 5.09K | 92.75K | (667.21K) | 705.15K |
| Other Non-Cash Items | 216.93K | 163.19K | 297.49K | 173.32K | 173.68K |
| Operating Cash Flow | (9.38M) | (12.91M) | (7.43M) | (10.64M) | (9.81M) |
| Capital Expenditures | (28.73K) | (5.01K) | (21.3K) | (895) | 0 |
| Acquisitions (Net) | 0 | 5.01M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (59.88M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 19.88M | 39.93M | 0 | 0 |
| Other Investing Activities | 0 | (5.01M) | 0 | 198 | (2.9K) |
| Investing Cash Flow | (28.73K) | (40.01M) | 39.91M | (697) | (2.9K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.89M | 7.92K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.26K) | 0 | 0 | 0 | 244.02K |
| Financing Cash Flow | 20.78M | 7.92K | 0 | 0 | 244.02K |
| Effect of Forex Changes | 26.55K | (16.81K) | 17.27K | 3.96K | 15.68K |
| Net Change in Cash | 11.39M | (52.93M) | 32.49M | (10.64M) | (9.55M) |
| Free Cash Flow | (9.41M) | (12.92M) | (7.45M) | (10.64M) | (9.81M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.